 Englewood Cliffs, NJ, June 08, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTCQB: SILO a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement SRA with the University of California San Francisco UCSF. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinsons, Bipolar disorder, and chronic back pain. 